ATYR · NASDAQ
aTYR PHARMA (ATYR) Stock Price & Fundamentals
aTYR PHARMA (ATYR) closed at $587.62 on Oct 9, 2026, up 0.05% from the previous close of $587.33.
Share price, past year
1Y +0.56%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $587.62 |
| Sep 30, 2026 | $597.58 |
| Aug 31, 2026 | $589.82 |
| Jul 31, 2026 | $620.49 |
| Jun 30, 2026 | $641.63 |
| May 29, 2026 | $703.02 |
| Apr 30, 2026 | $694.24 |
| Mar 31, 2026 | $658.08 |
| Feb 27, 2026 | $667.66 |
| Jan 30, 2026 | $665.02 |
| Dec 31, 2025 | $659.48 |
| Nov 28, 2025 | $668.01 |
| Oct 31, 2025 | $600.61 |
Key statistics
- Market cap
- $57.64B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.63
- Revenue (TTM)
- $190.00K
- Net income (TTM)
- −$60.81M
- Shares outstanding
- 98.1M
- Dividend yield
- —
- 52-week range
- $574.50 – $703.02
aTYR PHARMA's market cap is $57.64B, based on a share price of $587.62 and 98.1M shares outstanding as of Jun 30, 2026.
Financials
aTYR PHARMA reported revenue of $190.00K for fiscal 2025, down 19.15% from fiscal 2024.
aTYR PHARMA reported a net loss of $74.12M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $190.00K | −19.2% | −$74.12M | −39,009.5% | −$0.80 | −$62.06M |
| FY2024ended Dec 31, 2024 | $235.00K | −33.4% | −$64.02M | −27,243.8% | −$0.86 | −$69.18M |
| FY2023ended Dec 31, 2023 | $353.00K | −96.6% | −$50.39M | −14,274.5% | −$0.94 | −$37.44M |
| FY2022ended Dec 31, 2022 | $10.39M | — | −$45.34M | −436.5% | −$1.60 | −$43.53M |
| FY2021ended Dec 31, 2021 | $0.00 | −100.0% | −$33.77M | — | −$1.77 | −$33.27M |
| FY2020ended Dec 31, 2020 | $10.46M | +2,377.5% | −$16.22M | −155.2% | −$1.77 | −$15.50M |
| FY2019ended Dec 31, 2019 | $422.00K | — | −$16.22M | −3,844.6% | −$7.03 | −$20.09M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q4 FY2025ended Dec 31, 2025 | $0.00 | −$13.96M | −$0.15 |
| Q3 FY2025ended Sep 30, 2025 | $190.00K | −$25.74M | −$0.26 |
| Q2 FY2025ended Jun 30, 2025 | $0.00 | −$19.53M | −$0.22 |
| Q1 FY2025ended Mar 31, 2025 | $0.00 | −$14.88M | −$0.17 |
| Q4 FY2024ended Dec 31, 2024 | $0.00 | −$14.97M | −$0.17 |
| Q3 FY2024ended Sep 30, 2024 | $0.00 | −$17.26M | −$0.23 |
| Q2 FY2024ended Jun 30, 2024 | $0.00 | — | — |
| Q1 FY2024ended Mar 31, 2024 | $235.00K | — | — |
Company profile
- Name
- aTYR PHARMA INC
- Ticker
- ATYR
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 10240 Sorrento Valley Road, Suite 300, San Diego, CA 92121
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001339970
Recent SEC filings
- Sep 24, 2026
- Aug 7, 2026
- Aug 7, 2026
- Jul 31, 2026
- Jun 8, 2026
- Jun 1, 2026
- May 15, 2026
- May 15, 2026
Frequently asked questions
What is aTYR PHARMA's stock price?
aTYR PHARMA (ATYR) closed at $587.62 on Oct 9, 2026, up 0.05% from the previous close of $587.33.
What is aTYR PHARMA's market cap?
aTYR PHARMA's market cap is $57.64B, based on a share price of $587.62 and 98.1M shares outstanding as of Jun 30, 2026.
How much revenue does aTYR PHARMA make?
aTYR PHARMA reported revenue of $190.00K for fiscal 2025, down 19.15% from fiscal 2024.
Does aTYR PHARMA pay a dividend?
aTYR PHARMA's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from aTYR PHARMA INC's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures